Evidence map›Paper›PMID 36457288›Full record

ArticleDrug delivery2023

Aptamer-mediated hollow MnO

Ziyue Wang, Cuicui Wu, Jinren Liu, Shunxin Hu, Junli Yu, Qiangqiamg Yin, Hongda Tian, Zhipeng Ding, Guiqiang Qi, Li Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Advances of MnOFrontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ziyue WangDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Cuicui WuDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Jinren LiuDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Shunxin HuDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Junli YuDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Qiangqiamg YinDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Hongda TianDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Zhipeng DingDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Guiqiang QiDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Li WangDepartment of Personnel, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Liguo HaoDepartment of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Qiqihar Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sorafenib (SRF) presents undesirable effects in clinical treatment, due to the lack of targeting, poor water solubility, and obvious side effects. In this study, we constructed a novel nanodrug carrier system for accurate and efficient delivery of SRF, improving its therapeutic effects and achieving tumor-specific imaging. The hollow mesoporous MnO

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsDimapritGlypicansHumansManganese CompoundsMiceOligonucleotidesOxidesSorafenibTumor MicroenvironmentAPTDimapritGlypicansGPC3 protein, humanManganese CompoundsOligonucleotidesOxidesSorafenibdrug delivery systemHCCHollow mesoporous MnO2MR imaging

Identifiers

PMID36457288
PMCPMC9721444
OpenAlexW4310776874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.